Zenas BioPharma, Inc. (ZBIO) Stock Statistics & Valuation Metrics

Zenas BioPharma, Inc. has a market cap or net worth of $460.59M. The enterprise value is ―.

Zenas BioPharma, Inc. has 41,834,183 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zenas BioPharma, Inc.’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -52.14%.

The current PE Ratio of Zenas BioPharma, Inc. is -2.19. Zenas BioPharma, Inc.’s PEG ratio is 0.11.

In the last 12 months, Zenas BioPharma, Inc. had revenue of 5.00M and earned -156.13M in profits. Earnings per share was -3.76.

In the last 12 months, operating cash flow was -119.67M and capital expenditures -131.00K, giving a free cash flow of -119.81M billion.

Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Zenas BioPharma, Inc. upcoming earnings date is May 15, 2025, TBA Not Confirmed.

Zenas BioPharma, Inc. as a current ratio of 6.21, with Debt / Equity ratio of 0.32%

In the past 12 months, Zenas BioPharma, Inc. has paid -429.00K in taxes.

Zenas BioPharma, Inc. EV to EBITDA ratio is -0.14, with an EV/FCF ratio of -0.20.

Zenas BioPharma, Inc. has $350.77M in cash and marketable securities with $1.00M in debt, giving a net cash position of -$349.76M billion.

Gross margin is 100.00%, with operating margin of -3277.76%, and net profit margin of -3122.60%.

The average price target for Zenas BioPharma, Inc. is $36.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy